- Global Locations -


Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705


Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531


Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates


Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market Outlook 2022-2032

Valued at US$ 10.5 Billion in 2022, the global anaplastic large cell lymphoma (ALCL) therapeutics market is expected to develop at a CAGR of 5% over the next ten years. By the end of this forecast year in 2032, analysts anticipate the anaplastic large cell lymphoma (ALCL) therapeutics market share would be worth US$ 17.1 Billion.



Market Size Value (2022)

US$ 10.5 Billion

Market Size Value (2032)

US$ 17.1 Billion

Market Growth Rate (2022-2032)


The growing burden of cancer patients around has surfaced as a major concern around the world. Moreover, the increasing percentage of ALCL patients is quite alarming for many nations' healthcare systems necessitating private players' assistance to curb this problem in a systemic approach. Several market players operating in the healthcare sector have recognized this as a business expansion opportunity.

The United States, with its robust healthcare infrastructure and advanced medical science, has been favorable for the establishment of many market players in the country. So, it is the leading region in terms of higher demand for anaplastic large cell lymphoma (ALCL) therapeutics as patients from all over the world reach here to avail of the service.

However, with economic development and strengthening healthcare infrastructure in Asia-Pacific countries in recent years, this region has also witnessed ample opportunities for market growth. The prevalence of the disease in the countries like China and India is expected to increase the adoption of anaplastic large cell lymphoma (ALCL) therapeutics and strengthen the foundation for new market players to compete in the global market.

As per the global anaplastic large cell lymphoma (ALCL) therapeutics market survey report, hospitals are figured out to be the dominant end-user segment in comparison to any other type of healthcare institution. However, with the establishment of a number of specialized Cancer treatment and care institutes in present years, the market share of the hospitals is anticipated to drop marginally.

Lymphoma is the most common type of blood cancer that affects that develops in the lymphatic system. Lymphoma are of two major types: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Lymphoma is caused when lymphocytes, type of white blood cells of the immune system grow and multiply uncontrollably.

Cancerous lymphocytes may travel to different parts of the body, including the spleen, blood, lymph nodes, bone marrow, and form a mass called a tumor. The two type of lymphocytes that can develop into lymphoma - B-lymphocytes (B-cells) and T-lymphocytes (T-cells).

Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma and a common subtype of T-cell lymphoma. ALCL consists of only 2% of NHLs and approx. 20% of T-cell lymphomas. ALCL symptoms includes fever, painless swelling of lymph nodes, weight loss, tiredness, backache and excessive night sweats.

It is comprised of two sub-types, based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL

According to National Cancer Institute, in the 2016, an estimated 1,685,210 new cases of cancer will be diagnosed in the United States and 595,690 people will die from the disease. NHL is the sixth most commonly diagnosed cancer in both men and women in the US.

In 2015, it is estimated that there will be 71,850 new cases of NHL (39,850 men and 32,000 women) and 19,790 deaths from NHL. According to GLOBOCAN 2012 estimates the incidence and mortality rate of NHL is 2.7% and 2.4% respectively.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Following drugs are being tested for ALCL

  • Alisertib (MLN8237)
  • Bortezomib (Velcade)
  • Combination of brentuximab vedotin and chemotherapy
  • Crizotinib (Xalkori)

With the increasing geriatric population and rate of diagnosis will boost the overall market for ALCL therapeutics. Moreover, significant increase in the healthcare spending will boost the ALCL therapeutics market during the forecast period.

Geographically the ALCL therapeutics market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and MEA region. The areas with the highest incidence of NHL are North America, Europe, and Australasia, as well as several countries in Africa and South America. Also, more than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world’s cancer deaths occur in these regions.

The ALCL can appear on body parts such as skin, organs and other part of the body, they grow slowly and are present on body for longer duration before diagnosis. ALCL that appears on skin is known as primary cutaneous ALCL.

Most common types of side effects observed are skin redness and skin irritation is caused. It is being observed that 10 percent primary cutaneous ALCL extends beyond the skin to organ or lymph. Systemic ALCL is parted depending on abnormal form of a protein on their surface called ALK or do not have abnormal form of a protein.

These are fast growing and the disease condition in ALK-positive (with abnormal protein) is different from ALK-negative (without abnormal protein). ALK-positive ALCL patients are treated with chemotherapy treatments, patients initially respond to the treatment but relapse within five years, these are found in children’s as well as adults.

ALK-negative ALCL patients are treated with stem cell transplantation after remission, these are mostly found in patients above 55 years.

Some major companies in the ALCL therapeutics market are Pfizer, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Seattle Genetics, Inc., Sareum Holdings PLC, Merck Sharp & Dohme Corp., Celgene Corporation and Valeant Pharmaceuticals North America LLC.

  • Anaplastic large cell lymphoma (ALCL) therapeutics Market Segments
  • Anaplastic large cell lymphoma (ALCL) therapeutics Market Dynamics
  • Historical Actual Market Size, 2013 - 2015
  • Anaplastic large cell lymphoma (ALCL) therapeutics Treatment Market Size & Forecast 2016 to 2026
  • Anaplastic large cell lymphoma (ALCL) therapeutics Treatment Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Anaplastic large cell lymphoma (ALCL) therapeutics Market Drivers and Restraints

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Anaplastic Large Cell Lymphoma Alcl Therapeutics Market

The global ALCL therapeutics market is segmented on the basis of route of administration, therapeutic areas and region

Segmentation based on Disease Type:

  • Primary ALCL
  • Relapsed ALCL

Segmentation based on Treatment Type:

  • Chemotherapy
  • (CHOP) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
  • Brentuximab vedotin
  • Pralatrexate
  • Surgery
  • Radiation therapy
  • Stem cell transplant

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Frequently Asked Questions

What is the Growth Outlook for Anaplastic Large Cell Lymphoma Market?

The market is likely to register a CAGR of 5% through 2032.

What is the Current Valuation of the Market?

The market is currently valued at US$ 10.5 Bn in 2022.

How is the Future of the Market?

The market is likely to grow to a valuation of US$ 17.1 Bn by 2032.

Which is the Leading Region in the Market?

North America is likely to be a leading market during the forecast period.

Explore Healthcare Insights

View Reports

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market

Schedule a Call